产品
编 号：F432411
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 706808-37-9
产品详情
生物活性：
Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants.
体内研究：
Belatacept (intraperitoneal injection, 60 mg/kg) inhibits ABMR (Antibody-Mediated Rejection), and inhibits acute rejection when combined with BTLA (B and T lymphocyte attenuator) overexpression therapy.Belatacept (intravenous injection, 20 mg/kg) displays immunosuppressive activities in monkeys immunized with sheep red blood cell.Animal Model:Acute rejection model of orthotopic kidney transplantation in rats
Dosage:60 mg/kg
Administration:Intraperitoneal injection, at postoperative and 4 days after transplantation.
Result:Inhibited creatinine increase after kidney transplantation (combined with BTLA overexpression therapy).Reduced C4d in graft IF staining, and reduced CD138 infiltration and DSA production.
Animal Model:Rhesus monkeys immunized with sheep red blood cell
Dosage:Intra-operatively 10 mg/kg, on day 4 (15 mg/kg) and on post-operative days 14, 28, 42, 56, 70 (20 mg/kg).
Administration:intravenous injection
Result:Caused a 50% reduction in the peak anti-SRBC response.Prolonged renal allograft survival and synergies with conventional immunosuppression.
体外研究：
Belatacept (0-5 mg/mL, 1 h) inhibits T-cell proliferation in a dose-dependent manner.Belatacept (500 ng/mL, 7 days) enhances predominance of effector-memory T-cells after allogeneic stimulation.Belatacept (100, 500 ng/mL, 7 days) has no effect on differentiation and allogeneic IFNγ production of isolated effector-memory T cells.Belatacept (10?μg/mL, 1 h) does not inhibit follicular T Cell-dependent B-Cell differentiation.Belatacept (40?μg/mL, 10 days) reduces plasmablast differentiation, Ig production, and the major transcription factor Blimp-1 in a T cell-independent manner.Belatacept (40?μg/mL, 30 min) induces activation of the STAT3 transcription factor in stimulated B cells and reduced the expression of CD86.
Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants.
体内研究：
Belatacept (intraperitoneal injection, 60 mg/kg) inhibits ABMR (Antibody-Mediated Rejection), and inhibits acute rejection when combined with BTLA (B and T lymphocyte attenuator) overexpression therapy.Belatacept (intravenous injection, 20 mg/kg) displays immunosuppressive activities in monkeys immunized with sheep red blood cell.Animal Model:Acute rejection model of orthotopic kidney transplantation in rats
Dosage:60 mg/kg
Administration:Intraperitoneal injection, at postoperative and 4 days after transplantation.
Result:Inhibited creatinine increase after kidney transplantation (combined with BTLA overexpression therapy).Reduced C4d in graft IF staining, and reduced CD138 infiltration and DSA production.
Animal Model:Rhesus monkeys immunized with sheep red blood cell
Dosage:Intra-operatively 10 mg/kg, on day 4 (15 mg/kg) and on post-operative days 14, 28, 42, 56, 70 (20 mg/kg).
Administration:intravenous injection
Result:Caused a 50% reduction in the peak anti-SRBC response.Prolonged renal allograft survival and synergies with conventional immunosuppression.
体外研究：
Belatacept (0-5 mg/mL, 1 h) inhibits T-cell proliferation in a dose-dependent manner.Belatacept (500 ng/mL, 7 days) enhances predominance of effector-memory T-cells after allogeneic stimulation.Belatacept (100, 500 ng/mL, 7 days) has no effect on differentiation and allogeneic IFNγ production of isolated effector-memory T cells.Belatacept (10?μg/mL, 1 h) does not inhibit follicular T Cell-dependent B-Cell differentiation.Belatacept (40?μg/mL, 10 days) reduces plasmablast differentiation, Ig production, and the major transcription factor Blimp-1 in a T cell-independent manner.Belatacept (40?μg/mL, 30 min) induces activation of the STAT3 transcription factor in stimulated B cells and reduced the expression of CD86.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备